Atsena Therapeutics
PrivateLast Round
Series C
Apr 2, 2025
Est. Valuation
$340M
Total Funding Raised
$237.62M
Company Overview
Atsena Therapeutics operates in Healthcare & Life Sciences and is based in Durham, North Carolina. Its latest recorded funding round was a Series C round in April 2025.
Atsena Therapeutics is a biotechnology company that develops ocular gene therapies aimed at reversing or preventing blindness caused by inherited retinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atsena Therapeutics Comparables
Compare Atsena Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Opus Genetics | 86% | |
| Beacon Therapeutics | 85% | |
| SpliceBio | 81% |
For institutional investors. Book with your work email.
Atsena Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 2, 2025 | ||||
| Series B | Aug 28, 2023 | ||||
| Series A | Dec 16, 2020 | ||||
| Series 1 | Apr 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Atsena Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series C |
| Lightstone Ventures | Series A, Series C, Series B |
| Hatteras Venture Partners | Series A, Series C, Series B, Series 1 |
| Osage University Partners | Series A, Series C, Series B, Series 1 |
| The Manning Family Foundation | Series A, Series B, Series C |
| PBM Capital Group | Series 1 |
| Abingworth | Series A, Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 1, 2026
Grew 15% QoQ, from 39 to 45 employees.
- May 17, 2026
Monthly visitors grew 115% MoM, reaching 18.9K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 30, 2026
Atsena Therapeutics, Inc. presented 18-month safety and efficacy results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial at the American Academy of Optometry 2026 Annual Meeting in California from Sept 30th-Oct 3rd '26.
- is_developingAug 19, 2026
Atsena Therapeutics, Inc. develops ATSN-101 for GUCY2D-associated Leber congenital amaurosis type 1, or LCA1, through an exclusive strategic collaboration with Nippon Shinyaku Co. Ltd.; the program completes a Phase 1/2 trial and is expected to enter a global pivotal Phase 3 study in H2 '26.
- hiresAug 19, 2026
Atsena Therapeutics, Inc. appoints Matt Pauls, a rare disease commercial leader with more than 25 years of biotechnology and pharmaceutical leadership, to its Board of Directors in North Carolina on Aug 19th '26 as it advances two late-stage inherited retinal disease gene therapy programs toward pivotal trials and potential commercialization.
For institutional investors. Book with your work email.
Atsena Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Atsena Therapeutics's valuation, stock price, and market status.
Is Atsena Therapeutics a public or private company?
Atsena Therapeutics is a private company.
What is the current stock price of Atsena Therapeutics?
Atsena Therapeutics is a private company, so its shares have no public market price. Caplight tracks Atsena Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Atsena Therapeutics worth (valuation)?
Atsena Therapeutics's valuation is estimated at $340.0M based on funding round data.
Can I buy Atsena Therapeutics stock?
Atsena Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Atsena Therapeutics's last funding round?
Atsena Therapeutics's most recent funding round was Series C on April 2, 2025.
Who are the main investors in Atsena Therapeutics?
Key investors in Atsena Therapeutics include Bain Capital Life Sciences, Hatteras Venture Partners, Bain Capital, LP, Foundation Fighting Blindness, Sofinnova Investments.
Will Atsena Therapeutics IPO soon?
No public IPO plans have been announced for Atsena Therapeutics.
How can I track Atsena Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Atsena Therapeutics's shares on secondary markets.